Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort

PHASE4CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

October 13, 2015

Primary Completion Date

May 4, 2017

Study Completion Date

May 4, 2017

Conditions
COPD
Interventions
DRUG

QVA149 110/50 micrograms

QVA149 110/50 micrograms o.d. capsules for inhalation, supplied in blisters via a single dose dry powder inhalater (SDDPI)

DRUG

Salmeterol/fluticasone 50/500 microgrammes

Salmeterol/fluticasone 50/500 microgrammes b.i.d.dry inhalation powder delivered via Accuhaler / Diskus device

Trial Locations (64)

470

Novartis Investigative Site, Hazmiyeh

652

Novartis Investigative Site, Saida

1000

Novartis Investigative Site, Manila

1100

Novartis Investigative Site, Quezon City

2047

Novartis Investigative Site, Drummoyne

2145

Novartis Investigative Site, Westmead

2193

Novartis Investigative Site, Johannesburg

2450

Novartis Investigative Site, Coffs Harbour

3020

Novartis Investigative Site, Bulacan

4000

Novartis Investigative Site, San Pablo City, Laguna

4001

Novartis Investigative Site, Durban

4068

Novartis Investigative Site, Phoenix

4217

Novartis Investigative Site, Lipa City

4870

Novartis Investigative Site, Cairns

5041

Novartis Investigative Site, Daw Park

5042

Novartis Investigative Site, Bedford Park

5064

Novartis Investigative Site, Glen Osmond

6150

Novartis Investigative Site, Murdoch

6301

Novartis Investigative Site, Beirut

7500

Novartis Investigative Site, Cape Town

7764

Novartis Investigative Site, Gatesville

11525

Novartis Investigative Site, Riyadh

11566

Novartis Investigative Site, Cairo

13100

Novartis Investigative Site, Sefad

15586

Novartis Investigative Site, Kota Bharu

21131

Novartis Investigative Site, Alexandria

21423

Novartis Investigative Site, Jeddah

22060

Novartis Investigative Site, New Taipei City

25100

Novartis Investigative Site, Kuantan

25240

Novartis Investigative Site, Erzurum

33079

Novartis Investigative Site, Mersin

34000

Novartis Investigative Site, Taiping

34854

Novartis Investigative Site, Istanbul

35040

Novartis Investigative Site, Izmir

35110

Novartis Investigative Site, Yenisehir/Izmir

40705

Novartis Investigative Site, Taichung

42080

Novartis Investigative Site, Konya

49100

Novartis Investigative Site, Petah Tikva

58100

Novartis Investigative Site, Tel Giborim, Holon

59100

Novartis Investigative Site, Kuala Lumpur

61080

Novartis Investigative Site, Trabzon

63514

Novartis Investigative Site, Al Fayyum

78278

Novartis Investigative Site, Ashkelon

83301

Novartis Investigative Site, Kaoshiung

84101

Novartis Investigative Site, Beersheba

91031

Novartis Investigative Site, Jerusalem

91120

Novartis Investigative Site, Jerusalem

93586

Novartis Investigative Site, Kuching

98000

Novartis Investigative Site, Miri

110029

Novartis Investigative Site, New Delhi

166378

Novartis Investigative Site, Beirut

166830

Novartis Investigative Site, El Achrafiyé

440010

Novartis Investigative Site, Nagpur

3525408

Novartis Investigative Site, Haifa

7610001

Novartis Investigative Site, Rehovot

1503201002

Novartis Investigative Site, El Chouf

380 008

Novartis Investigative Site, Ahmedabad

400 012

Novartis Investigative Site, Nagpur

160 062

Novartis Investigative Site, Mohali

641 045

Novartis Investigative Site, Coimbatore

1107 2020

Novartis Investigative Site, Beirut

Unknown

Novartis Investigative Site, Linkou District

01330

Novartis Investigative Site, Adana

09100

Novartis Investigative Site, Aydin

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY